SRR2016951
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.430
- ALLOGRAFT_REJECTION+0.280
- KRAS_SIGNALING_DN+0.260
- OXIDATIVE_PHOSPHORYLATION+0.250
- IL6_JAK_STAT3_SIGNALING+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- XENOBIOTIC_METABOLISM+0.190
- COAGULATION+0.180
- DNA_REPAIR+0.180
Top 10 suppressed
- PROTEIN_SECRETION-0.470
- G2M_CHECKPOINT-0.420
- MITOTIC_SPINDLE-0.410
- UV_RESPONSE_DN-0.400
- ANDROGEN_RESPONSE-0.360
- E2F_TARGETS-0.330
- HEDGEHOG_SIGNALING-0.310
- MTORC1_SIGNALING-0.260
- PI3K_AKT_MTOR_SIGNALING-0.240
- TGF_BETA_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.879 |
| 2 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.870 |
| 3 | TCGA-CV-A45T-01A-11R-A24H-07 | — | — | 0.826 |
| 4 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.819 |
| 5 | TCGA-OL-A66H-01A-11R-A29R-07 | — | B | 0.802 |
| 6 | TCGA-AC-A5XS-01A-11R-A29R-07 | — | B | 0.802 |
| 7 | MNG718 | — | — | 0.797 |
| 8 | TCGA-CV-A461-01A-41R-A266-07 | — | — | 0.790 |
| 9 | MNG580 | — | — | 0.785 |
| 10 | MNG445 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |